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Abstract: Although our understanding of Parkinson’s disease (PD) has improved and effective
treatments are available, caring for people with PD remains a challenge. The large heterogeneity in
terms of motor symptoms, nonmotor symptoms, and disease progression makes tailored individual
therapy and individual timing of treatment necessary. On the other hand, only limited resources are
available for a growing number of patients, and the high quality of treatment cannot be guaranteed
across the board. At this point, networks can help to make better use of resources and improve
care. The working group PD Networks and Integrated Care, part of the German Parkinson Society,
is entrusted to convene clinicians, therapists, nurses, researchers, and patients to promote the
development of PD networks. This article summarizes the work carried out by the working group
PD Networks and Integrated Care in the development of standards of network care for patients with
PD in Germany.
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1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disorder (after
Alzheimer’s disease) and is predicted to increase in prevalence as the population ages [1]. Classically,
PD is characterized by motor symptoms, namely, tremors, rigidity, and bradykinesia. However,
the clinical phenotype of PD is highly variable, and a wide range of nonmotor symptoms
(NMSs) underpins the clinical stages of PD. These NMSs, such as neurobehavioral disorders,
cognitive impairment, and gastrointestinal dysfunction, are, by all accounts, very common in
individuals with PD and contribute to poor quality of life [2]. The appearance of motor symptoms and
NMSs vary throughout the disease course, which provides a challenge for care management not only for
the neurologist but also for the general practitioner (GP), who is a frequent care contact for the patient.
There are many pharmacologic therapies currently available, such as tablets, patches, pens, and pumps;
deep brain stimulation (DBS) as an established surgical intervention; magnetic resonance (MR)-guided
focused ultrasound as a new innovative procedure; and nonpharmacological interventions such as
physiotherapy, speech therapy, and occupational therapy.
Importantly, the number of patients that are hospitalized for treatment of PD is constantly rising in
Germany, and there are substantial regional differences in the availability of specialized treatment [3,4].
Definitively, clinical heterogeneity, as well as the availability of a wide variety of specialized therapeutic
procedures, makes multiprofessional care necessary. PD requires close interactions between different
care partners, for example, GPs, neurologists, therapists, nursing staff, social workers, and PD
nurse specialists. However, the reality of treatment is that there are often significant gaps in care [5].
Proven structural concepts for the care of patients with PD are currently not well established in Germany.
For example, it is not specified who should make the diagnosis of PD, who initiates and continues
treatment and who continuously ensures guideline-adapted procedures [6]. In particular, the planning
and implementation of therapy options for advanced PD reach their limits without an optimal setting.
In Germany, people with PD are treated in general neurological practices, specialist medical practices,
outpatient clinics, medical care centers, general university outpatient departments, and specialized
university outpatient departments, as well as in GP practices. Insufficient communication between the
various players can lead to different approaches to diagnostics and therapy and ultimately decrease
patient adherence. In addition, patients increasingly request a so-called second or third opinion in
specialized PD centers.
In recent years, it has been recognized that the formation of networks can contribute to improving
the care of patients with PD. The establishment of networks for the treatment of patients with PD is a
great challenge due to inhomogeneous regional conditions, the lack of a suitable technical infrastructure,
and the strict regulation and separation of the individual sectors in the German health care system [7].
PD networks generally aim to improve the care of patients with PD at various levels by involving
different actors in the inpatient and outpatient sectors, thereby additionally reducing costs [8]. The most
important components of PD networks are, among others, the bundling of expertise of different,
specially trained professionals (professional empowerment), a strong and active involvement of
patients in the care process (patient empowerment), and the networking of professionals with special
expertise in the field of PD (team empowerment) [9]. In Germany, different approaches and methods
for treating patients with PD have been established as a result of different regional characteristics.
Networks can help to make diagnostics more accurate, faster, and more effective, while avoiding
duplicate examinations [7]. In addition to traditional outpatient, semi-inpatient, and inpatient
treatment, practice visits and telemedical methods can be used to optimize therapy in networks [10,11].
Several factors are crucial for a successful and functioning network: a specialized team, the application
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of evidence-based treatment guidelines, the selection of motivated practitioners, regular training,
commitment to compliance with the guidelines, patient-centered treatment, and transparent outcome
quality [9,12]. The core element of patient care within a network should be the implementation of a
standardized treatment pathway. This defines the best possible sequence of treatment steps on the
basis of guidelines and medical expertise. If possible, all patients within a network should be treated
with specialized neurologists, registered neurologists, and GPs working in a collaborative manner.
There should be flowing boundaries to allow equal, individual care concepts based on medical necessity.
In our opinion, the establishment of such a treatment pathway must be individually oriented in each
network to the corresponding network structures, regional characteristics, and resources available
in each case, making simple transferability between different networks impossible. Nevertheless,
core elements will certainly be available in different networks. This review, therefore, provides an
overview of evidence-based recommendations for the network care of patients with PD within the
framework of a multisectoral, multiprofessional setting.
2. Roundtable Participants and Format
The authors met in Cologne in 2019 for a roundtable discussion and to organize the foundation of
the working group PD Networks and Integrated Care, part of the Deutsche Gesellschaft für Parkinson
und Bewegungsstörungen (DPG). The working group has the following aims: synchronization of
supply networks in Germany, development of minimum standards, development of joint research
projects, further development of nursing staff qualifications, and development of qualification standards
for therapy groups. The DPG working group pursues the goal of improving patient care in close
cooperation with other physicians, therapists, and patient support groups. The roundtable discussion
was sponsored by DPG (travel costs). Following introductions and stated aims, various points of
interest (existing German network structures and aims, communication strategies, standards of network
care, etc.) were discussed. No formal votes were taken at the meeting. The discussions identified
general points of agreement.
3. The Patient Journey—Where to Go When PD Is Suspected?
To give recommendations for a standard of network care, one has to acknowledge the existing
care paths for patients with PD in Germany. Typically, the initial symptoms are not identified as
Parkinsonism or PD-specific symptoms by the patients themselves. Instead, they usually approach their
GP with motor or even more important and frequent nonmotor complaints (e.g., obstipation, pain and
depression). Occasionally, physiotherapists treating back pain or degenerative joint symptoms realize
that these are the first signs of motor symptoms (e.g., rigidity) related to PD and that the patient should
be referred for a PD diagnostic workup.
Patients who live in rural areas are more likely to have their GP identify symptoms as being
related to PD (13). However, the GP model in Germany is not as rigid as in other countries, and many
citizens not only have a primary care physician but can also consult specialists (e.g., internal medicine,
orthopaedists, etc.), depending on their prior health care contacts and requirements throughout
their lifetime.
4. What Symptoms and Complaints Should Prompt a GP to Consider a Diagnosis of PD,
and When Should a Neurologist Be Consulted?
Parkinsonism refers to a clinical presentation characterized by the presence of bradykinesia plus
rest tremor or rigidity [13]. Bradykinesia is a generalized slowing of movements and repetitive motion
fatigue. It may present as hypomimia (“masked face”), hypophonia, worsening of fine-motor tasks,
micrographia, difficulty turning in bed, or reduced arm swing with side difference. Additionally,
distinct changes of gait and balance, like short steps, shuffling gait, and uncertainty when turning
around are common. Rigidity is the resistance that can be assessed clinically by passively flexing and
extending a patient’s limb. Typically, the patient complains about stiffness and pain, which often
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manifests as shoulder or back pain. While kinetic and postural tremors may occur, the rest tremor
is the most common type of tremor in early PD. Patients with these clinical signs should be referred
to a neurologist for further diagnosis, because, in Germany, the time between the appearance of the
first symptoms and the diagnosis is significantly longer when patients with these symptoms see their
GP [5]. Patients with symptoms that may be related to PD should be asked about PD-typical nonmotor
signs such as sensory symptoms (loss of smell, pain), depressed mood, rapid eye movement–sleep
behavior disturbance, periodic limb movement disorder, or constipation, which frequently occur years
before motor signs are realized.
Thus, one recommendation for standard of care in the initial phase of the disease course is
physician awareness of the first signs of PD (which could be achieved with better information and
secondary prevention standards in the network) and early referral of patients to a movement disorder
specialist (which could be achieved by specific disease management programmes). The movement
disorder specialist should be a neurologist with many years of experience caring for patients with
PD. In Germany, there are specific recommendations for patient referral in this context that can guide
decisions in the outpatient setting [6].
5. What Diagnostic Tests Should Be Performed by the Neurologist at the First Visit?
In 2015, the official International Parkinson and Movement Disorder Society (MDS) Clinical
Diagnostic Criteria for PD were proposed [13]. The benchmark for these criteria is an expert
clinical diagnosis. However, the criteria can be easily applied by clinicians with less expertise in PD
diagnosis [14].
In the MDS criteria, motor symptoms remain the core feature of the disease, defined as
bradykinesia plus rest tremor or rigidity (explicit instructions for defining these symptoms are
given). After consideration of absolute exclusion criteria (which rule out PD), red flags, and supportive
criteria, the diagnosis of clinically established PD or probable PD can be made, or PD can be ruled out.
Besides anamnesis, clinical assessment with cerebral imaging (cranial MR imaging [MRI]
is preferred) should be performed to exclude symptomatic causes of PD symptoms. In case
of divergent clinical and MRI-based diagnoses, the clinical assessment should take precedence.
However, a differentiated approach is required for the numerous subsequent apparatus and drug tests.
The evidence shows that levodopa and apomorphine tests are not as meaningful as standard levodopa
therapy in differentiating between established PD and atypical Parkinson’s syndrome. A negative test
does not rule out a response to longer-lasting levodopa treatment. This suggests that levodopa and
apomorphine tests should not be routinely used in differential diagnosis but may be valuable in specific
clinical situations [15]. A reduction in olfactory capacity is a sensitive but not specific indicator of PD.
Therefore, standardized olfactory tests are only recommended in combination with other diagnostic
procedures for the diagnosis of PD. Striatal dopamine active transporter-single photon emission
computed tomography (SPECT) imaging should be used early in the course of the disease to detect
a nigrostriatal deficit in clinically unexplained parkinsonism or tremor syndrome [15]. In contrast,
the postsynaptic (I 123-iodobenzamide) SPECT should not be used for the differential diagnosis of
established Parkinson’s syndrome (syn. Idiopathic Parkinson Syndrome) to differentiate atypical
neurodegenerative disease variants. The myocardial 123 MIBG-SPECT can be used to distinguish
multiple system atrophy from PD [15]. In addition, functional brain imaging with positron emission
tomography is a valuable diagnostic tool for the differential diagnosis of idiopathic Parkinson Syndrom
and atypical parkinsonism [16,17].
For clinical neurological confirmation of the diagnosis and therapy control, the patient should
be examined after 3 months, and thereafter according to clinical need but at least once a year [15].
Because even proven experts have to revise the diagnosis of an IPS during the course of the disease,
the diagnosis should be reviewed at regular intervals. With the rising availability of electronic patient
records, another recommendation is that a standard set of information should be generated and stored
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in the record of each patient with PD after the results of the first diagnostic tests. This information
should be available for the patient and his or her health care provider team.
6. Which Patients Should Be Referred to a Specialized Movement Disorder Center?
Referral to a movement disorder specialist is important to improve the accuracy of diagnosis,
for case selection and to provide guidance in terms of specialized device-aided therapies, namely,
DBS, levodopa/carbidopa intestinal gel (LCIG) and apomorphine. Consultation from the medical staff
of a specialized center may improve motor function and the quality of life in patients in advanced
PD stages [18,19]. Patients with the following constellations and symptoms should be referred to a
movement disorder specialist even if the disease duration is <4 years [20–22]:
• Doubts about correct diagnosis;
• Young onset and side effects under prescribed medication;
• Troublesome motor fluctuations;
• ≥1 h of troublesome dyskinesia/day;
• ≥2 h ‘off’ symptoms/day;
• ≥5 oral levodopa doses/day;
• Freezing of gait;
• Acute or subacute camptocormia;
• High burden of NMS;
• Nontransitory troublesome hallucinations;
• Repeated falls despite assumed treatment.
Referral to a movement disorder specialist should also be considered for the patient to have
access to the most innovative treatment and clinical research options. A substantial number of patients
are highly interested in contributing to research, the opportunities for which are typically limited
to regional neurologists. Recommendations for these patient referrals in the outpatient setting in
Germany have been proposed [6].
7. Which Patients Should Be Admitted for PD Multimodal Complex Treatment (MCT)?
Some health care insurance systems reimburse treatment of patients with PD in specialized units.
A well established and frequently used multiprofessional inpatient treatment concept in Germany
is PD multimodal complex treatment (PD-MCT). Prerequisites for patients taking part in MCT are
documented physician diagnosis of PD, a constant anti-Parkinsonian drug titration, and the application
of activating therapies (at least 7.5 h/week). It involves physicians, physiotherapists, occupational
therapists, speech therapists, and other specialists for the optimization of PD treatment [3] and usually
lasts 7 to 21 days. This therapy programme has been shown to be effective, with a reduction of motor
symptoms and NMS [23,24]. Richter et al. [3] performed an analysis of 55,141 inpatients with PD who
were integrated into this MCT from 2010–2016. They found that a large majority of patients with PD
need to leave their residence county for an inpatient stay in a specialized PD unit. This limited access
to multimodal therapy programmes means that patients sometimes have to travel long distances to
receive specialized therapy [3]. There are no generally valid definitions of which patients should
be treated within the complex programme and which should not. In view of the heterogeneity, it is
difficult to make binding statements about this.
A prerequisite should be that the motor or NMSs can no longer be satisfactorily treated by
outpatient therapy. Another prerequisite should be that patients are dealing with limitations in their
activities of daily life and have a reduced quality of life. This can be the case, for example, with side
effects under oral therapy, motor deterioration, or the high burden of NMS. Other typical indications
for inpatient treatment would be the discontinuation of DBS or the initiation and optimization of
therapy with LCIG or apomorphine. However, as the disease progresses and progressive limitations in
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mobility and cognition are observed, the benefits of inpatient treatment must be weighed against the
increasing risk of delirium.
Overall, clinical experience shows a substantial benefit of PD-MCT for a large number of patients.
The preselection process could ideally be managed by network structures and players. Additionally,
the positive effect achieved by intense medical and nonmedical intervention should be maintained
after release by immediate intensified ambulatory intervention and home-training concepts in order
for the patients to benefit from the positive experience. This would be an important incentive for the
patient to take part in PD-MCT.
8. Which Patients Should Be Admitted to a PD Day Clinic?
For patients with PD who need to adapt to complex medication schemes, drug pumps, or DBS
devices, a classical outpatient or inpatient setting is not appropriate to sufficiently address clinical
problems, while in a neurologist’s office or even in a movement center, outpatient clinic time and staff
capacities are limited and the results of changes in medication or stimulation of the DBS device can
only be monitored in the next (often late) consultation. An in-house stay is associated with an artificial
environment that does not reflect the individual’s everyday life demands and is less suited for patients
with dementia who often cannot cope with an altered environment. Furthermore, many patients with
PD decline hospitalization for personal reasons such as job issues or having to care for other family
members. For these patients, at the border between inpatient and outpatient care and the need for
sophisticated treatment strategies, the new comprehensive, individual, and interdisciplinary concept
of a PD day clinic has proven to be effective [25]. In the meantime, in Germany, several university
clinics with a PD focus have established this or a similar PD day clinic concept to close the gap in PD
care that have been found to be a transnational issue [26–28]. The concepts and standards of qualified
PD day clinics have been certified recently by the TÜV and the German Parkinson Patient Society [29].
9. Who Else Should Be Involved in the Treatment of Patients with PD?
In general, a neurologist should be responsible for long-term medical care of patients with PD,
and movement disorder specialists should be involved when there is a special issue. However,
for various reasons, this is not always possible. Neurologists may not be available in rural areas,
and even for patients in nursing homes, access to specialized neurological treatment is often limited.
This is an important issue, because the number of patients in long-term care facilities will rise sharply
in the coming decades [30]. For patients with PD, the interaction between the GPs and neurologists
is essential. PD networks can make a decisive contribution to ensuring high-quality care of these
patient groups.
Medical treatment is not the only option to control the motor symptoms and NMS during the course
of the disease. Other nonmedical treatment options from other specialists are frequently necessary to
improve functional status, performance of daily activities, and quality of life. These specialists include,
among others, physiotherapists, occupational therapists, speech therapists, PD nurse specialists,
and social workers [31]. Specific recommendations for physiotherapists, physicians, and patients with
PD were published in the European Physiotherapy Guidelines for Parkinson’s Disease [32].
Health professionals must have sufficient PD-specific knowledge and expertise [33].
Physiotherapy has a positive impact on functional activities involving gait, transfers, and balance [32,34].
The occupational therapist focuses on enabling performance and engagement in meaningful
activities [35]. Home-based, individualized occupational therapy can improve the self-perceived
performance of daily activities in patients with PD [36]. Timely referral to physiotherapy,
and occupational therapy is recommended because difficulties in daily activities can occur in
every disease stage. Given the high prevalence of dysphagia and dysarthria during the course of the
disease [37], speech-language therapy, including swallowing techniques, is frequently necessary for
patients with PD. A collaborative approach between these disciplines should focus on complementary
and different aspects. Therapists have to be aware of each other’s expertise, and effective and timely
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communication is essential [35]. PD networks are promising tools to share information about diagnostic
results, current treatment goals, and plans.
In addition, there are many different nonphysician PD specialists for inpatient and outpatient care,
such as PD nurse specialists or Parkinson assistants (PASSs). Their different roles and functions are
described in another paper in this Issue. Depending on the location (inpatient or outpatient), the focus
of their tasks can be different. These specialists are often familiar with aspects of case management;
medication adherence; provision of information, education, psychosocial support, and coping skills;
and caregiver support [38]. Patients with PD should have 1) regular access to clinical monitoring
and adjustment of medication in consultation with the treating physician; 2) regular contact with
caregivers, including home visits, as appropriate; and 3) access to reliable sources of information on
clinical and social issues affecting patients with PD and their caregivers/families. These functions
could be provided by PD nurse specialists or a PASS. The positive therapeutical effects of PD nurse
specialists are currently evaluated for their health economic impact [39].
In particular, patients with advanced PD may benefit early from palliative care. Doctors and
nursing staff can provide information about the final phase so that the family can take advantage of
adequate care options. Palliative care should be aligned with patient priorities and complement other
treatments. Therefore, advanced care planning might also increase knowledge about end of life issues.
Generally, it should start early in the course of the disease. It can be started when particular symptoms
occur (pain, dyspnoea, dysphagia, and aspiration) or at the very end of life [40,41]. Besides general
markers of advanced disease (frequent infections and hospitalizations, malnutrition, etc.), the palliative
performance scale can be used to measure the functional status of a patient and to determine the
eligibility for enrolment in a palliative care programme [41,42]. Dysphagia with symptomatic aspiration
might be taken as a clear indicator when palliative care should begin, because it also involves a
discussion about life-prolonging therapies such as tube feeding.
Figure 1 provides an overview of common players and structures in a local supply network.
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The therapist network (outpatient) directly surrounding the patient and his or her environment
is not only linked to the patient, but therapists are also linked to each other. This results in mutual
inter-relationships and a flow of information between all professional groups involved (not only between
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the directly neighbouring ones). A supraregional supply network in the form of clinics and centers is
connected to this ‘’micro-network”. Here, exchange and cooperation results. Different stationary and
semistationary care options are offered and supplemented with, for example, telemedical services
(e.g., medical video observation and sensor-based motion analysis).
10. What Is the Relevance of Self-Management in Patients with PD?
Self-management means having knowledge, skills, and confidence to manage daily tasks
when living with a chronic disorder such as PD. It includes the concepts of self-management
tasks (medical, role, and emotional management) and self-management skills (problem solving,
decision-making, resource utilization, the formation of a patient–provider partnership, action-planning,
and self-tailoring) [43]. Patients with PD should be able to monitor progress and problems and to set,
communicate, and harmonize their individual therapeutic goals with all members of the health care
provider team. In addition, required information for the individual aspects of the disease symptoms,
treatments, and side effects/risks should be tailored to the patient requirements and transferred
adequately to the patient. Health care providers involved in the care of patients with PD can positively
influence self-management skills with distinct approaches that mainly focus on education and support.
Self-management in PD may, therefore, contribute to slower disease progression, reduced complications,
and lowered costs [44]. However, self-management support interventions for patients with PD vary in
content, structure, and intensity, and little is known about which existing self-management support
programmes are most effective. As indicated by a recent overview of self-management support
programmes for patients with PD, clinicians should ensure that the key components of education,
goal setting, and guided problem solving are included. Moreover, adding these skills to the
rehabilitation process and including caregivers and peer support systems seems promising [44].
11. What Is the Role of Telemedicine in the Network Care of Patients with PD?
As mentioned above, PD requires close interaction between different care partners in order to
provide the best possible care for the patient. Rural location, nursing home residence, and the presence
of physical or cognitive impairment are common reasons for limited access to specialized PD health
care [45]. A PD network can improve access to specialized health care and manage the distribution
of resources, tasks, and responsibilities. By doing so, PD networks can help to avoid unnecessary
hospitalization and reduce costs [8]. Different methods exist to bring PD-specific knowledge and care
to the patients in a PD network structure. In this context, telemedicine has shown promising effects for
the management of PD. This includes synchronous methods (videoconferencing) and asynchronous
methods (e.g., e-mail, smartphone assessments, remote monitoring, and wearable devices) [10,11,46].
Telemedicine has the potential to allow PD-specific efficient care to be delivered to more patients and
more regularly than a traditional model of care [47]. From the patient’s view, telemedicine has the
advantages of access to specialists, convenience, and time savings [48]. At present, it is applied in
several clinical settings due to sanctions imposed for infection prophylaxis in the current sars-cov-2
pandemic, and it is seen to be a suitable tool with which to give advice and treat patients with PD.
It also can be used to support outpatient palliative care teams with special neurological knowledge
when the patient chooses to die at home [49]. Since 2019, the remuneration of video consultation hours
has been based on the insured, basic, or consultation flat rate in Germany. Nevertheless, telemedicine is
still limited by patients’ limited access to high-speed internet and usability issues (especially in
elderly patients) [46]. Nevertheless, with the new Digital Health Act (‘’Digitale-Versorgung-Gesetz”
(DVG)), reimbursement for video-based home telemedicine support has begun in Germany, and now,
home telemedicine needs to be integrated into PD health care workflows.
12. Future Directions
The German health care system is struggling with the issues of separation of care sectors (e.g.,
outpatient vs. inpatient care) and considerable differences in the provision of care in urban and
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rural areas. In order to optimize the specialized care of patients with PD in Germany, the current
care structures must be changed. This can be achieved by establishing PD networks, which act
as a link between outpatient and inpatient treatment as well as between patients, caregivers, GPs,
nonspecialized neurologists, movement disorder specialists, and other therapists. This is a promising
way to ensure that a stage-appropriate and patient-specific therapy for PD can be initiated promptly
and maintained permanently in accordance with the current guidelines. Additionally, new e-health
processes might overcome current barriers and limited access to specialized health care and provide
both patients and health care professionals with the potential for future seamless care, a strong
interaction between health care partners, and involvement of patients and caregivers. Interestingly,
many patients with PD are using digital media tools and smartphones and thus have access to
digital technology [50]. Furthermore, the recently released Digital Health Act (DVG) will enable
patient-centered technologies as digital health care applications for better support of trans-sectoral PD
health care.
Especially against the background that some studies have found only limited benefits from
specialized network structures, it is very important to provide scientific support for the formation
of networks in Germany. These studies from England or the Netherlands that focus on very limited
aspects (e.g., PD nurses, physiotherapy) are only transferable to Germany to a limited extent [33,51].
Decision makers, planners, and managers need evidence-based policy options and information on
the scope of networks [52]. The DPG working group Networks and Integrated Care is therefore
an opportunity to provide a framework for various forms of networks, to facilitate the exchange
of experience, and to provide scientific support for the various structures and networks with their
regional characteristics.
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